QYQianhua Yan

Qianhua Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qianhua Yan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Jiangyi Yu

    Department of Endocrinology, Jiangsu Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

    2 shared publications
  • Xiqiao Zhou

    Department of Endocrinology, Jiangsu Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

    2 shared publications
  • Ying Tan

    Department of Endocrinology, Jiangsu Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

    2 shared publications
  • Bo Jia

    College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    1 shared publication
  • Heng-Chang Hu

    College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    1 shared publication
  • Jun-Yu Liu

    College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    1 shared publication

Latest Publications

  • Open Access

    New insights into diagnostic values and mechanisms of ferroptosis associated with immune infiltration in diabetic kidney disease

    by Ying Tan, Zihui Liu, Siyuan Song, Lingling Zhu, Yun She, Xiqiao Zhou, Jiangyi Yu, Qianhua Yan

    The pathogenesis of diabetic kidney disease (DKD) is complex and closely related to ferroptosis and immune dysregulation, but the relevance is unclear. The present study investigates the potential mechanisms of ferroptosis‑related genes (FRGs) in DKD and their relationship with the immune‑inflammatory response. It searches for new diagnostic biomarkers to help diagnose and treat DKD. Four Gene Expression Omnibus (GEO) datasets, GSE30528, GSE30529 and GSE30122 as the test set, and GSE96804 for validation, were analyzed. FRGs were obtained from GeneCards, and 47 ferroptosis‑related differentially expressed genes (FRDEGs) were identified by intersecting with DKD‑related differentially expressed genes. Functional enrichment analyses, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Gene Set Enrichment Analysis and Gene Set Variation Analysis, revealed that these FRDEGs are primarily associated with ferroptosis, hypoxia response and immune inflammation. Subsequently, the weighted gene co‑expression network analysis (WGCNA) was employed to expand the ferroptosis‑related gene network, and intersection of the 47 FRDEGs with key WGCNA module genes yielded 10 key genes. Based on the 10 key genes, the least absolute shrinkage and selection operator and support vector machine algorithms identified three hub genes [chemokine ligand 5 (CCL5), forkhead box C1 (FOXC1) and lactotransferrin (LTF)] for DKD diagnosis. Receiver operating characteristic curves confirmed their diagnostic value, with FOXC1 and LTF validated in the independent dataset. Immune infiltration analysis via CIBERSORT revealed eight immune cell types with significantly different infiltration levels between the DKD and control group in the integrated GEO datasets. Notably, both LTF and CCL5 showed a significant positive correlation with gamma delta T cells (γδT). Quantitative PCR results confirmed differential expression of the three hub genes in the DKD group, with elevated expression observed in DKD mice following intervention with rosiglitazone and hyperoside.

  • Top Cited Papers
    Open Access

    Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems

    by Li Song, Wei Zhang, Shi-Yun Tang, Si-Min Luo, Pei-Yu Xiong, Jun-Yu Liu, Heng-Chang Hu, Ying-Qi Chen, Bo Jia, Qian-Hua Yan, et al.


  • Open Access

    Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study

    by Ying Tan, Ruihan Li, Peipei Zhou, Nan Li, Weilong Xu, Xiqiao Zhou, Qianhua Yan, Jiangyi Yu

    Objective: We aimed to explore the value of Huobahuagen tablet (HBT) in improving decreased renal function for patients with diabetic kidney disease (DKD) over time.Methods: This was a single-center, retrospective, real-world study on eligible 122 DKD patients who continued to use HBT + Huangkui capsule (HKC) therapy or HKC therapy without interruption or alteration in Jiangsu Province Hospital of Chinese Medicine from July 2016 to March 2022. The primary observation outcomes included estimated glomerular filtration rate (eGFR) at baseline and 1-, 3-, 6-, 9-, and 12-month follow-up visits and changes in eGFR from baseline (ΔeGFR). Propensity score (PS) and inverse probability treatment weighting (IPTW) were used to control for confounders.Results: eGFR was significantly higher in the HBT + HKC group than in the HKC alone group at the 6-, 9-, and 12-month follow-up visits (p = 0.0448, 0.0002, and 0.0037, respectively), indicating the superiority of HBT + HKC over HBT alone. Furthermore, the ΔeGFR of the HBT + HKC group was significantly higher than that of the HKC alone group at the 6- and 12-month follow-up visits (p = 0.0369 and 0.0267, respectively). In the DKD G4 patients, eGFR was higher in the HBT + HKC group at the 1-, 3-, 6-, 9-, and 12-month follow-up visits compared with baseline, with statistically significant differences at the 1-, 3-, and 6- month follow-up visits (p = 0.0256, 0.0069, and 0.0252, respectively). The fluctuations in ΔeGFR ranged from 2.54 ± 4.34 to 5.01 ± 5.55 ml/min/1.73 m2. Change in the urinary albumin/creatinine ratio from baseline did not exhibit a significant difference between the two groups at any of the follow-up visits (p > 0.05 for all). Adverse event incidence was low in both groups.Conclusion: The findings of this study based on real-world clinical practice indicate that HBT + HKC therapy exhibited better efficacy in improving and protecting renal function with a favorable safety profile than HKC therapy alone. However, further large-scale prospective randomized controlled trials are warranted to confirm these results.